An enantioselective covalent inhibitor of BAX confers cytoprotection in vivo.
Shi P, Melillo B, McHenry MW, Camara CM, Yang K, Njomen E, Godes M, Pazyra-Murphy MF, Branch MR, Tesar B, Segal RA, Rubin LL, Cameron MD, Bird GH, Wales TE, Gygi SP, Cravatt BF, Walensky LD
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Subbiah V, Zhao F, Kudchadkar RR, Sullivan RJ, Chen HX, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Sundaresan TK, Conley BA, Tricoli JV, Arteaga CL, Wright JJ, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT
Defective microhomology-mediated end joining in -deficient tumors.
Zhu G, Asada S, Nguyen H, Hirohashi Y, Sun L, Saravanapavan A, Rahmani E, Hrynashka M, Mukkavalli S, Batish M, Shapiro GI, D'Andrea AD
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial.
Al-Samkari H, Shatzel JJ, Panch SR, Keating JH, Walsh EP, Weekes CD, Kardosh A, Cohen SA, Cohen JJ, Hodges PG, Dhaver SE, Strojny N, Donovan C, Belibasakis C, Soff GA
PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.
Hao J, Kochupurakkal B, Branigan TB, Somuncu OS, Liu R, Jadhav H, da Costa AAB, Jiao Y, Yu JZ, Martignetti DB, Sadatrezaei G, Mukkavalli S, Gokhale PC, Cheng SC, Skates SJ, Nasioudis D, Konstantinopoulos PA, Liu JF, Gaillard SL, Giuntoli Ii RL, Martin LP, Tanyi JL, Latif N, Heller IS, Simpkins F, Parmar K, D'Andrea AD, Shapiro GI
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.
Smoragiewicz M, Bernard-Tessier A, Linch M, Shen J, Shore ND, Parikh O, Chi KN, Sokolova AO, Culine S, McKean M, Gleave M, Devitt ME, Zhi E, Gong J, Landrette S, Colasanto M, Patel V, Gao X
Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods.
Lynce F, Liu X, Li B, McRoy L, Chen C, Liu R, Rugo HS
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.
Shitara K, Shoji H, Fazio N, Lonardi S, Lee KW, Bai LY, Yamaguchi K, Metges JP, Masi G, Smith D, Kim TY, Matsangou M, Shrivastava A, Zhou M, Hill J, Guerrero A, Wang X, Zaanan A, Klempner SJ
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.
Al-Samkari H, Muñoz C, Geredeli Ç, Korantzis I, González Astorga B, Arslan C, Cordeiro Camargo JF, Scotté F, Borges G, Wang K, Eisen M, Kuter DJ, Soff GA
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
van Tienen LM, Bayoumi S, Muneeruddin K, Leymarie N, Popa A, Shekhar M, Mueller M, Li R, Zak KM, Chilukuri H, Kornfilt DJP, Atack TC, Kesar D, Bian Y, Shaw KL, Jandova Z, Trollmann P, Geist L, Stolt-Bergner P, Rumpel K, Kessler D, Sellers WR
Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.
Coleman N, Wei Z, Iafrate AJ, Zwiebel JA, Sharon E, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Williams T, Croley JJ, Onitilo AA, Tricoli JV, Cheng J, Karlovich C, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Hong DS, Chen AP, Flaherty KT
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.
Fece de la Cruz F, Varkaris A, Patel PS, Kushner EW, Morales-Giron AA, Lee SS, Singh A, Kim CT, Norden BL, Ehnstrom S, Riedl JM, Curtis JM, Barnes H, Kehlmann AM, Chevalier NJ, Okuma HS, Patel M, Wirth LJ, Connell B, Nugent F, Pappas L, Lau K, Juric D, Hopkins JL, Guiley KZ, Shokat KM, Gulhan DC, Parikh AR, Corcoran RB
